ArticleInfection and drug resistance2025
Clinical Characterization, Risk Factors, and Mortality in Patients with Carbapenem-Resistant Hypervirulent
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Molecular characterization of carbapenem resistance and hypervirulence determinants of Klebsiella pneumoniae circulating in a tertiary hospital in Cyprus.Molecular biology reports · 2026Article
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- A nomogram for predicting 30-day mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a retrospective cohort study.BMC infectious diseases · 2026Article
- Machine learning-assisted prognostic model for mortality in ICU patients with culture-confirmedFrontiers in cellular and infection microbiology · 2026Article
- Clinical Epidemiological Analysis of the Genotypic Spectrum and Mortality Risk in Carbapenem-ResistantThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Review
- Virulence and Genomic Profiles of Klebsiella pneumoniae Isolated from Pediatric Patients in Henan, China (2021-2023).Current medical science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The outbreak of the highly lethal Carbapenem-resistant Methods: The study included 160 patients who developed CRKP IAIs from June 2023 to December 2024. Carbapenemase and virulence genes were detected by Polymerase chain reaction assay. Antimicrobial susceptibility test was performed to determine drug resistance. Multivariate logistic regression and multivariate Cox regression were used to determine risk factors of CR-hvKP IAIs and CRKP IAIs mortality, respectively. Results: A total of 160 patients with CRKP IAIs were enrolled: 68 with CR-hvKP IAIs and 92 with CR-non-hvKP IAIs. The mortality rate trended higher in the CR-hvKP group compared with CR-non-hvKP (17.6% vs 10.9%), but the difference was not statistically significant (P=0.218). Multivariate logistic regression identified tracheotomy as a risk factor for infection with CR-hvKP IAIs (OR 2.816, 95% CI 1.120-7.080). Multivariate Cox regression analysis identified four independent risk factors for in-hospital mortality of CRKP IAIs: age (HR 1.066, 95% CI 1.020-1.114), decreased platelet count (HR 0.995, 95% CI 0.990-0.999), septic shock (HR 9.141, 95% CI 2.082-40.133), and tracheotomy (HR 4.322, 95% CI 1.461-12.791). Conclusion: The mortality rate was numerically higher in the CR-hvKP IAIs while the difference was not statistically significant. Our study identified tracheotomy as an independent risk factor for infection with CR-hvKP IAIs. Clinicians need to enhance their awareness and epidemiologic surveillance of this lethal bacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.